Everything below concerns pharmacokinetics. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
=== Proteins === The chromatographic purification of proteins from complex mixtures can be quite challenging, particularly when the mixtures contain similarly retained proteins or when it is desired to enrich trace components in the feed. Further, column loading is often limited when high resolutions are required using traditional modes of chromatography (e.g. linear gradient, isocratic chromatography). In these cases, displacement chromatography is an efficient technique for the purification of proteins from complex mixtures at high column loadings in a variety of applications. An important advance in the state of the art of displacement chromatography was the development of low molecular mass displacers for protein purification in ion exchange systems. This research was significant in that it represented a major departure from the conventional wisdom that large polyelectrolyte polymers are required to displace proteins in ion exchange systems. Low molecular mass displacers have significant operational advantages as compared to large polyelectrolyte displacers. For example, if there is any overlap between the displacer and the protein of interest, these low molecular mass materials can be readily separated from the purified protein during post-displacement processing using standard size-based purification methods (e.g. size exclusion chromatography, ultrafiltration). In addition, the salt-dependent adsorption behavior of these low MW displacers greatly facilitates column regeneration.
Glycosidic bonds of the form discussed above are known as O-glycosidic bonds, in reference to the glycosidic oxygen that links the glycoside to the aglycone or reducing end sugar. In analogy, one also considers S-glycosidic bonds (which form thioglycosides), where the oxygen of the glycosidic bond is replaced with a sulfur atom. In the same way, N-glycosidic bonds, have the glycosidic bond oxygen replaced with nitrogen. Substances containing N-glycosidic bonds are also known as glycosylamines. C-glycosyl bonds have the glycosidic oxygen replaced by a carbon; the term "C-glycoside" is considered a misnomer by IUPAC and is discouraged. All of these modified glycosidic bonds have different susceptibility to hydrolysis, and in the case of C-glycosyl structures, they are typically more resistant to hydrolysis.
It is also under development for the treatment of primary membranous nephropathy, idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis), Graves'' ophthalmopathy, antibody-mediated rejection (AMR), immune-mediated necrotizing myopathy, anti-synthetase syndrome, dermatomyositis, polymyositis, immune thrombocytopenia, primary Sjögren's syndrome, rheumatoid arthritis and pemphigus.
Sources: en.wikipedia.org
In the first reaction the bidentate ligand ethylene diamine forms a chelate complex with the copper ion. Chelation results in the formation of a five-membered ring. In the second reaction the bidentate ligand is replaced by two monodentate methylamine ligands of approximately the same donor power, meaning that the enthalpy of formation of Cu–N bonds is approximately the same in the two reactions. Under conditions of equal copper concentrations and when the concentration of methylamine is twice the concentration of ethylenediamine, the concentration of the bidentate complex will be greater than the concentration of the complex with 2 monodentate ligands. The effect increases with the number of chelate rings so the concentration of the EDTA complex, which has five chelate rings, is much higher than a corresponding complex with two monodentate nitrogen donor ligands and four monodentate carboxylate ligands. Thus, the phenomenon of the chelate effect is a firmly established empirical fact: under comparable conditions, the concentration of a chelate complex will be higher than the concentration of an analogous complex with monodentate ligands. The thermodynamic approach to explaining the chelate effect considers the equilibrium constant for the reaction: the larger the equilibrium constant, the higher the concentration of the complex.
== Formulation of the rule == This rule is derived from the fact that, perhaps coincidentally, for the most common chemical elements in neutral organic compounds (hydrogen, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur, and the halogens), elements with even numbered nominal masses form even numbers of covalent bonds, while elements with odd numbered nominal masses form odd numbers of covalent bonds, with the exception of nitrogen, which has a nominal (or integer) mass of 14, but has a valency of 3. The nitrogen rule is only true for neutral structures in which all of the atoms in the molecule have a number of covalent bonds equal to their standard valency (counting each sigma bond and pi bond as a separate covalent bond for the purposes of the calculation). Therefore, the rule is typically only applied to the molecular ion signal in the mass spectrum. Mass spectrometry generally operates by measuring the mass of ions. If the measured ion is generated by creating or breaking a single covalent bond (such as protonating an amine to form an ammonium center or removing a hydride from a molecule to leave a positively charged ion) then the nitrogen rule becomes reversed (odd numbered masses indicate even numbers of nitrogens and vice versa). However, for each consecutive covalent bond that is broken or formed, the nitrogen rule again reverses.
corrects this dilution effect by multiplying the fraction of the susceptible population over the total population. It corrects the effective/transmissible interaction between an infectious person and the rest of the community when many of the interaction is immune in the middle to late stages of the disease spreading. Thus, when
Sources: en.wikipedia.org
Willie Limond, 45, Scottish boxer and footballer (Albion Rovers), complications from a seizure. 18 April – Dave Moyes, 68, Scottish footballer (Berwick Rangers, Meadowbank Thistle, Dunfermline Athletic). 23 April – Fergie MacDonald, 86, Scottish accordionist. 28 April – Brian McCardie, 59, Scottish actor (Rob Roy, Speed 2: Cruise Control, Ellie Parker) and writer. 29 April – Christian, 80, Scottish singer and entertainer. 3 May – Jim Rodger, 90, Scottish footballer (St Mirren, Rangers, Queen of the South). 14 May – Gudrun Ure, 98, Scottish actress (Super Gran, The Million Pound Note, The Crow Road). 20 May – Gerry Collins, 69, Scottish football player (Ayr United, Hamilton Academical, Partick Thistle) and manager. 22 May – David Wilkie, 70, Scottish swimmer, Olympic champion (1976), world champion (1973, 1975), cancer. 24 May – Stuart Borrowman, 71, Scottish politician. 29 May – John Burnside, 69, Scottish writer and poet. 5 June – David Scott, 83, Scottish journalist and broadcaster (Scottish Daily Express, BBC Scotland, STV). (death announced on this date) 18 June – Billy Abercromby, 65, Scottish footballer (St Mirren, Partick Thistle, Dunfermline Athletic). (death announced on this date) 26 June – Pat Heywood, 92, actress (Lucky Feller, Wuthering Heights, Inspector Morse, Root Into Europe) 27 June – Donald Scott, 96, Scottish rugby union player (Langholm, South of Scotland District, national team). 28 July – John Anderson, 92, Scottish television personality (Gladiators). 4 August – Jim Doherty, 65, Scottish footballer (Kilmarnock, Clyde, Queen of the South).
== 2018 suicide attempt and introduction to DMT == On January 15, 2018, Cantelmo contacted his children and told them he intended to kill himself. Police placed him on a 5150 hold, an involuntary psychiatric detention. While in the facility he decided to try DMT after his release. After leaving the hospital he ordered mimosa hostilis root bark online, extracted DMT using methods based on his chemistry background, and began experimenting with the substance. He later described a breakthrough experience that ended his lifelong atheism and convinced him of the existence of a higher power and of entities he encountered during the trips. He resolved to promote DMT publicly.
1,3-Dibromopropane is an organobromine compound with the formula (CH2)3Br2. It is a colorless liquid with sweet odor. It is used in organic synthesis to form C3-bridged compounds such as through C-N coupling reactions. 1,3-Dibromopropane was used in the first cyclopropane synthesis in 1881, known as the Freund reaction.
α-Methylthiofentanyl is an opioid analgesic that is an analogue of fentanyl. α-Methylthiofentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. α-Methylthiofentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.